Loading clinical trials...

Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event | Clinical Trials | Clareo Health

COMPLETED

Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event

An Open-label, Multicentre, Phase 3 Study to Demonstrate the Prognostic Usefulness of 123I-mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event During 24 Months Followup

NCT00785044•GE Healthcare

View on ClinicalTrials.gov

Summary

The study was designed to study the utility of meta-iodobenzylguanidine (123I-mIBG) imaging to identify those participants with heart failure who would experience an adverse cardiac event during 24 months of follow-up from the administration date of 123I-mIBG in previous studies MBG311 or MBG312.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•The subject was a Heart Failure subject who signed informed consent for MBG311, MBG312, or MBG312C.
•The subject was administered 123I-mIBG in MBG311, MBG312, or MBG312C.
•The subject completed the late planar imaging assessments (at a minimum) required by the protocols for MBG311, MBG312, or MBG312C.
•The subject agreed to allow the investigator access to medical records, including those relating to subject death should this occur.

Exclusion Criteria

•The subject withdrew or was withdrawn from MBG311, MBG312, or MBG312C.
•The subject was considered lost-to-follow-up (6 months without contact) in MBG311, MBG312, or MBG312C.

Locations (1)

GE Healthcare

Princeton, New Jersey, United States

Key Dates

Start Date

May 1, 2008

Primary Completion Date

January 1, 2010

Completion Date

February 1, 2010

Last Updated

April 26, 2017

Enrollment

471

ACTUAL participants

Conditions

Congestive Heart Failure

Interventions

I-123 mIBG

DRUG

TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer

NCT05507879

Breast CarcinomaCardiomyopathy+1 more

View study

RECRUITINGNA

Stress and Congestive Heart Failure

NCT04551560

Congestive Heart Failure

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 26, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event

Inclusion Criteria

Exclusion Criteria

TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer

Stress and Congestive Heart Failure

Eat Well Heart Failure

Peritoneal Ultrafiltration in Cardio Renal Syndrome.

SyncAV Post-Market Trial

Plasma ExtrAcellular RNAs and Biomarkers of Heart FaiLure During Decongestion: PEARL-HF Study